Tadalafil for the treatment of pulmonary arterial hypertension

Bibliography

• Badesch DB, Champion HC, Sanchez MA, Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S55-66
   PubMed Web of Science ®Google Scholar
• Simonneau G, Robbins IM, Beghetti M, Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S43-54
   PubMed Web of Science ®Google Scholar
• D'Alonzo GE, Barst RJ, Ayres SM, Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115(5):343-9
   PubMed Web of Science ®Google Scholar
• Galie N, Hoeper MM, Humbert M, Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30(20):2493-537
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173(9):1023-30
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011;8(8):443-55
   PubMed Web of Science ®Google Scholar
• Wise H. Multiple signalling options for prostacyclin. Acta Pharmacol Sin 2003;24(7):625-30
   PubMedGoogle Scholar
• Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263(5579):663-5
   PubMed Web of Science ®Google Scholar
• Olschewski H, Olschewski A, Rose F, Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 2001;138(5):287-97
   PubMedGoogle Scholar
• Tuder RM, Cool CD, Geraci MW, Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159(6):1925-32
   PubMed Web of Science ®Google Scholar
• Sastry BK. Pharmacologic treatment for pulmonary arterial hypertension. Curr Opin Cardiol 2006;21(6):561-8
   PubMed Web of Science ®Google Scholar
• Davie N, Haleen SJ, Upton PD, ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165(3):398-405
   PubMed Web of Science ®Google Scholar
• Chua BH, Krebs CJ, Chua CC, Diglio CA. Endothelin stimulates protein synthesis in smooth muscle cells. Am J Physiol 1992;262(4 Pt 1):E412-16
   PubMedGoogle Scholar
• Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61(2):227-37
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Kubac G, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 1991;18(1):38-43
   PubMedGoogle Scholar
• Miyauchi T, Yorikane R, Sakai S, Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993;73(5):887-97
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Sitbon O, Badesch DB, Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25(2):244-9
   PubMed Web of Science ®Google Scholar
• Beavo JA. cGMP inhibition of heart phosphodiesterase: is it clinically relevant? J Clin Invest 1995;95(2):445
   PubMedGoogle Scholar
• Ahn HS, Foster M, Cable M, Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 1991;308:191-7
   PubMedGoogle Scholar
• Galie N, Ghofrani HA, Torbicki A, Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353(20):2148-57
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Voswinckel R, Reichenberger F, Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004;44(7):1488-96
   PubMed Web of Science ®Google Scholar
• Jing ZC, Yu ZX, Shen JY, Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011;183(12):1723-9
   PubMed Web of Science ®Google Scholar
• Curran M, Keating G. Tadalafil. Drugs 2003;63(20):2203-12; discussion 13-4
   PubMedGoogle Scholar
• Tantini B, Manes A, Fiumana E, Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005;100(2):131-8
   PubMed Web of Science ®Google Scholar
• Michelakis E, Tymchak W, Lien D, Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105(20):2398-403
   PubMedGoogle Scholar
• Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003;92(9A):9M-18M
   PubMed Web of Science ®Google Scholar
• Yuasa K, Kanoh Y, Okumura K, Omori K. Genomic organization of the human phosphodiesterase PDE11A gene. Evolutionary relatedness with other PDEs containing GAF domains. Eur J Biochem 2001;268(1):168-78
   PubMedGoogle Scholar
• Guillaume M, Lonsdale F, Darstein C, Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. J Clin Pharmacol 2007;47(10):1303-10
   PubMed Web of Science ®Google Scholar
• Reffelmann T, Kieback A, Kloner RA. The cardiovascular safety of tadalafil. Expert Opin Drug Saf 2008;7(1):43-52
   PubMed Web of Science ®Google Scholar
• Kang DH, Lee JY, Park SY, Efficacy and safety of tadalafil 5 mg administered once daily in korean men with erectile dysfunction: a Prospective, Multicenter Study. Korean J Urol 2010;51(9):647-52
   PubMedGoogle Scholar
• Kloner RA, Hutter AM, Emmick JT, Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42(10):1855-60
   PubMedGoogle Scholar
• Park JW, Leithauser B, Jung F. Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition. Clin Hemorheol Microcirc 2008;39(1-4):323-8
   PubMedGoogle Scholar
• EMEA. Adcirca, tadalafil. European Public Assessment Report (EPAR). 2010;EMEA/753653/2009 EMEA/H/C/1021
   Google Scholar
• Beasley CM Jr, Mitchell MI, Dmitrienko AA, The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J Am Coll Cardiol 2005;46(4):678-87
   PubMedGoogle Scholar
• Ring BJ, Patterson BE, Mitchell MI, Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo. Clin Pharmacol Ther 2005;77(1):63-75
   PubMed Web of Science ®Google Scholar
• Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005;45(9):987-1003
   PubMed Web of Science ®Google Scholar
• Forgue ST, Phillips DL, Bedding AW, Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol 2007;63(1):24-35
   PubMed Web of Science ®Google Scholar
• Adcirca. Prescribing Information FDA. 2011 PV 6472 AMP
   Google Scholar
• Wrishko RE, Dingemanse J, Yu A, Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008;48(5):610-18
   PubMed Web of Science ®Google Scholar
• Spence R, Mandagere A, Harrison B, No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J Pharm Sci 2009;98(12):4962-74
   PubMed Web of Science ®Google Scholar
• Palmieri EA, Affuso F, Fazio S, Lembo D. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med 2004;141(9):743-4
   PubMed Web of Science ®Google Scholar
• Tay EL, Geok-Mui MK, Poh-Hoon MC, Yip J. Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients. Int J Cardiol 2008;125(3):416-17
   PubMed Web of Science ®Google Scholar
• Galie N, Brundage BH, Ghofrani HA, Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119(22):2894-903
   PubMed Web of Science ®Google Scholar
• Pepke-Zaba J, Beardsworth A, Chan M, Angalakuditi M. Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin 2009;25(10):2479-85
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Beardsworth A, Chan MLS, for the PHIRST Study group. Blinded, Long-Term Safety and Efficacy of Tadalafil in Treatment for Pulmonary Arterial Hypertension. American Thoracic Society meeting 2009 - Poster - A17; 2009
   Google Scholar
• Barst RJ, Oudiz RJ, Beardsworth A, Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2011;30(6):632-43
   PubMed Web of Science ®Google Scholar
• Bendayan D, Shitrit D, Kramer MR. Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study. Respirology 2008;13(6):916-18
   PubMed Web of Science ®Google Scholar
• Faruqi S, Fathi H, Morice AH. Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan. Int J Cardiol 2010;144(3):e43-5
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB. Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2010;11(1):127-32
   PubMed Web of Science ®Google Scholar